Work

Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study

Year: 2023
Type: article
Study design: Clinical Trial
Abstract: Background: Trastuzumab deruxtecan is classified as an anticancer agent that poses a moderate emetic risk in the international guidelines for antiemetic therapy.The guidelines recommend emesis prophylaxis using a two-drug combination therapy comprising a 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA) and dexamethasone (DEX).However, the high incidence of nausea and vomiting associated with trastuzumab deruxtecan is problematic.The National Comprehensive Cancer Network guideline version 1.2023 classified trastuzumab deruxtecan as having a high risk of emesis and changed its recommendation to a triplet regimen including a neurokinin-1 receptor antagonist (NK1RA).However, the emetogenic potential of trastuzumab-deruxtecan and the optimal antiemetic prophylaxis are Ivyspring International
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,337
OpenAlex ID: W4387098533
FWCI: 4.159
Cites: 18
Cited by: 19
Related to: 10